leucine chloromethyl ketone: RN given refers to parent cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 173830 |
| CHEMBL ID | 3247880 |
| SCHEMBL ID | 10021630 |
| MeSH ID | M0087985 |
| Synonym |
|---|
| 61727-69-3 |
| leucine chloromethyl ketone |
| 3-amino-1-chloro-5-methylhexan-2-one |
| 2-hexanone, 3-amino-1-chloro-5-methyl-, (s)- |
| leu-chloromethyl ketone |
| leucine cmk |
| CHEMBL3247880 |
| SCHEMBL10021630 |
| DTXSID00977309 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " All gave 50% growth inhibition of cultures of human epidemeroid carcinoma of the nasopharynx at dosage levels of 2-8 mug/ml while showing no activity against L1210 lymphoid leukemia in vivo in BDFi mice." | ( Synthesis and biological activity of potential antimetabolites. Glover, GI; Kaeder, GR; Nelson, SO, 1977) | 0.26 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1136485 | Antitumor activity against mouse L1210 cells allografted in BDF1 mouse | 1977 | Journal of medicinal chemistry, Mar, Volume: 20, Issue:3 | Synthesis and biological activity of potential antimetabolites. |
| AID1136484 | Cytotoxicity against human NCI-90KB cells assessed as growth inhibition | 1977 | Journal of medicinal chemistry, Mar, Volume: 20, Issue:3 | Synthesis and biological activity of potential antimetabolites. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (50.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.66) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||